[go: up one dir, main page]

RU2018131966A3 - - Google Patents

Download PDF

Info

Publication number
RU2018131966A3
RU2018131966A3 RU2018131966A RU2018131966A RU2018131966A3 RU 2018131966 A3 RU2018131966 A3 RU 2018131966A3 RU 2018131966 A RU2018131966 A RU 2018131966A RU 2018131966 A RU2018131966 A RU 2018131966A RU 2018131966 A3 RU2018131966 A3 RU 2018131966A3
Authority
RU
Russia
Application number
RU2018131966A
Other versions
RU2018131966A (ru
RU2748892C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018131966A publication Critical patent/RU2018131966A/ru
Publication of RU2018131966A3 publication Critical patent/RU2018131966A3/ru
Application granted granted Critical
Publication of RU2748892C2 publication Critical patent/RU2748892C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2018131966A 2016-03-21 2017-03-13 Рнк-репликон для универсальной и эффективной генной экспрессии RU2748892C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/056165 WO2017162266A1 (en) 2016-03-21 2016-03-21 Rna replicon for versatile and efficient gene expression
EPPCT/EP2016/056165 2016-03-21
PCT/EP2017/055808 WO2017162460A1 (en) 2016-03-21 2017-03-13 Rna replicon for versatile and efficient gene expression

Publications (3)

Publication Number Publication Date
RU2018131966A RU2018131966A (ru) 2020-04-22
RU2018131966A3 true RU2018131966A3 (ru) 2020-07-08
RU2748892C2 RU2748892C2 (ru) 2021-06-01

Family

ID=55587284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018131966A RU2748892C2 (ru) 2016-03-21 2017-03-13 Рнк-репликон для универсальной и эффективной генной экспрессии

Country Status (24)

Country Link
US (2) US11168337B2 (ru)
EP (2) EP3701959B1 (ru)
JP (2) JP7121443B2 (ru)
KR (1) KR102161607B1 (ru)
CN (2) CN108884473B (ru)
AU (1) AU2017236239B2 (ru)
CA (1) CA3017272A1 (ru)
CY (1) CY1125086T1 (ru)
DK (2) DK3701959T3 (ru)
ES (2) ES2906807T3 (ru)
HR (1) HRP20220044T1 (ru)
HU (2) HUE050350T2 (ru)
IL (2) IL261379B (ru)
LT (1) LT3701959T (ru)
MX (1) MX2018011383A (ru)
PL (2) PL3433369T3 (ru)
PT (2) PT3433369T (ru)
RS (1) RS62864B1 (ru)
RU (1) RU2748892C2 (ru)
SG (1) SG11201807374WA (ru)
SI (2) SI3433369T1 (ru)
SM (1) SMT202200047T1 (ru)
WO (2) WO2017162266A1 (ru)
ZA (1) ZA201805519B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP7389741B2 (ja) * 2017-09-13 2023-11-30 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー T細胞受容体または人工t細胞受容体を発現するためのrnaレプリコン
AU2018333503B2 (en) * 2017-09-13 2025-03-27 BioNTech SE RNA replicon for reprogramming somatic cells
WO2019137999A1 (en) 2018-01-11 2019-07-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3142935A1 (en) * 2019-06-10 2020-12-17 Infectious Disease Research Institute Methods and compositions of astrovirus replicons
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
CN110890127B (zh) * 2019-11-27 2024-02-23 山东大学 酿酒酵母dna复制起始区域识别方法
CN116134131A (zh) 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
WO2021160346A1 (en) 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
WO2021183563A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
TWI860474B (zh) * 2020-04-22 2024-11-01 德商拜恩迪克公司 冠狀病毒疫苗
AU2021271300A1 (en) * 2020-05-11 2023-02-02 Janssen Pharmaceuticals, Inc. RNA replicon encoding a stabilized corona virus spike protein
US20230265454A1 (en) * 2020-06-04 2023-08-24 BioNTech SE RNA Replicon for Versatile and Efficient Gene Expression
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
IL319926A (en) 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems
JP2024518335A (ja) 2021-04-26 2024-05-01 アンスティチュ パスツール SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
AU2022372325A1 (en) 2021-10-18 2024-05-02 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
WO2023066875A1 (en) 2021-10-18 2023-04-27 BioNTech SE Modified replicable rna and related compositions and their use
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
JP2024540978A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア オリゴ糖化合物及び複合体
US20240425541A1 (en) 2021-10-22 2024-12-26 BioNTech SE Oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
US20240417418A1 (en) 2021-10-22 2024-12-19 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
JP2024540979A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
JP2024543721A (ja) 2021-10-22 2024-11-22 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
JP2025509078A (ja) 2022-02-10 2025-04-11 アフィセル セラピューティクス カンパニー リミテッド Cd40lに特異的に結合するステフィンaタンパク質変異体及びその用途
CN114639442B (zh) * 2022-03-30 2024-01-30 中国农业科学院农业基因组研究所 一种基于单核苷酸多态性预测开放阅读框的方法及系统
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
JP2025518221A (ja) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア 核酸の送達のための複合体
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
CN120583964A (zh) 2022-09-26 2025-09-02 生物技术欧洲股份公司 核酸复合物及其用途
EP4605010A1 (en) 2022-10-21 2025-08-27 BioNTech SE Nucleic acid complexes and uses thereof
CN116153402B (zh) * 2023-02-03 2025-06-13 深圳元育生物科技有限公司 基于深度学习模型进行密码子序列设计的方法和装置
WO2024176192A1 (en) 2023-02-24 2024-08-29 BioNTech SE Immunogenic compositions
EP4442276A1 (en) 2023-04-07 2024-10-09 Institut Pasteur Combined antibodies against sarbecoviruses and uses thereof
WO2024236192A1 (en) 2023-05-17 2024-11-21 Institut Pasteur Heterodimer of poxvirus a16 and g9 proteins as an immunogen
WO2025027089A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thiolipids and uses thereof
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
TW202525287A (zh) 2023-12-21 2025-07-01 德商拜恩技術運輸科技有限責任公司 可離子化脂質
WO2025153707A1 (en) 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053780A2 (en) 1999-03-09 2000-09-14 Large Scale Biology Corporation Multiple component rna vector system for expression of foreign sequences
DE60233061D1 (de) 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
FR2862982B1 (fr) * 2003-12-02 2006-04-28 Genethon Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale.
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
ES2500515T3 (es) 2007-06-19 2014-09-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Síntesis y utilización de análogos de fosforotioato antiinversos de la caperuza de ARN mensajero
CN101802199B (zh) * 2007-06-21 2012-08-22 阿尔法瓦克斯公司 用于α病毒结构蛋白表达的无启动子盒
WO2009024567A1 (en) 2007-08-20 2009-02-26 Glaxo Group Limited Production method
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
SMT202300144T1 (it) 2010-08-31 2023-07-20 Glaxosmithkline Biologicals Sa Liposomi piccoli per la somministrazione di rna codificante un immunogeno
JP5908477B2 (ja) 2010-08-31 2016-04-26 ノバルティス アーゲー タンパク質をコードするrnaのリポソームによる送達に適した脂質
HRP20221023T1 (hr) 2010-08-31 2022-11-11 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za isporuku rna koja kodira imunogen
EP4098324A1 (en) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
EP4115876A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
PL2750707T3 (pl) 2011-08-31 2019-05-31 Glaxosmithkline Biologicals Sa Pegylowane liposomy do dostarczania rna kodującego immunogen
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences

Also Published As

Publication number Publication date
AU2017236239B2 (en) 2023-05-18
CA3017272A1 (en) 2017-09-28
JP7465310B2 (ja) 2024-04-10
JP2022169553A (ja) 2022-11-09
SI3433369T1 (sl) 2020-07-31
PL3433369T3 (pl) 2020-07-13
MX2018011383A (es) 2019-02-13
SI3701959T1 (sl) 2022-04-29
PT3433369T (pt) 2020-04-22
RU2018131966A (ru) 2020-04-22
US12281322B2 (en) 2025-04-22
SG11201807374WA (en) 2018-10-30
WO2017162460A1 (en) 2017-09-28
IL261379B (en) 2022-04-01
ES2906807T3 (es) 2022-04-20
HK1259449A1 (en) 2019-11-29
CN108884473A (zh) 2018-11-23
KR20180127356A (ko) 2018-11-28
HRP20220044T1 (hr) 2022-04-15
RS62864B1 (sr) 2022-02-28
AU2017236239A1 (en) 2018-09-20
CN108884473B (zh) 2022-08-09
RU2748892C2 (ru) 2021-06-01
EP3701959B1 (en) 2021-12-22
CY1125086T1 (el) 2023-06-09
EP3701959A1 (en) 2020-09-02
CN115927467A (zh) 2023-04-07
KR102161607B1 (ko) 2020-10-05
IL291100B1 (en) 2023-01-01
PT3701959T (pt) 2022-01-31
DK3701959T3 (da) 2022-01-17
WO2017162266A1 (en) 2017-09-28
IL291100B2 (en) 2023-05-01
US11168337B2 (en) 2021-11-09
EP3433369A1 (en) 2019-01-30
SMT202200047T1 (it) 2022-03-21
US20200299725A1 (en) 2020-09-24
LT3701959T (lt) 2022-03-10
HUE050350T2 (hu) 2020-12-28
DK3433369T3 (da) 2020-03-30
BR112018068381A2 (pt) 2019-01-15
IL261379A (en) 2018-10-31
CN115927467B (zh) 2025-08-29
EP3433369B1 (en) 2020-03-04
US20220033852A1 (en) 2022-02-03
ZA201805519B (en) 2019-11-27
JP7121443B2 (ja) 2022-08-18
JP2019509050A (ja) 2019-04-04
ES2784711T3 (es) 2020-09-30
IL291100A (en) 2022-05-01
HUE059139T2 (hu) 2022-10-28
PL3701959T3 (pl) 2022-02-28

Similar Documents

Publication Publication Date Title
RU2018131966A3 (ru)
BR202016030146U2 (ru)
CN303538757S (ru)
CN303538997S (ru)
CN303726525S (ru)
CN303690787S (ru)
CN303649758S (ru)
CN303649465S (ru)
CN303622790S (ru)
CN303617764S (ru)
CN303600594S (ru)
CN303592454S (ru)
CN303580636S (ru)
CN303579331S (ru)
CN303574417S (ru)
CN303564166S (ru)
CN303563619S (ru)
CN303559588S (ru)
CN303553038S (ru)
CN303551064S (ru)
CN303550509S (ru)
CN303545027S (ru)
CN303539396S (ru)
CN303539387S (ru)
CN303539267S (ru)